HALEOSLABS vs PPLPHARMA: Stock Comparison

Haleos Labs Limited vs Piramal Pharma Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Haleos Labs Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 9 of 13 scored metrics and PPLPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹484 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 27.94x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 3.01x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹-2.45
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0.08%
Revenue Growth (TTM YoY)
HALEOSLABS has faster revenue growth
0% vs -0.1%
Qtr Sales Growth
PPLPHARMA has stronger quarterly sales growth
-0.08% vs -15.7%
Qtr Profit Growth
PPLPHARMA has stronger quarterly profit growth
-25% vs -85.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSPPLPHARMA
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSPPLPHARMA
Live Price₹1,522.4₹177.14
Day Change-3.09%-4.15%
Volume28179.18 L
52-Week High₹1,774₹212.39
52-Week Low₹1,181₹132.3
Distance from 52W High-14.18%-16.6%

Valuation

MetricHALEOSLABSPPLPHARMA
Market Cap₹484 Cr₹23,554 Cr
P/E Ratio27.94x-75.43x
P/B Ratio2.27x3.01x
EPS₹57.3₹-2.45
Book Value₹706₹64.78
Dividend Yield0.1%0.08%

Growth

MetricHALEOSLABSPPLPHARMA
Revenue Growth (TTM YoY)0%-0.1%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-15.7%-0.08%
Qtr Profit Growth-85.2%-25%

Profitability & Leverage

MetricHALEOSLABSPPLPHARMA
ROE8.44%-3.83%
ROCE9.91%2.52%
Net Margin5.33%-3.68%
Operating Margin13.4%10.4%
Debt to Equity0.52x0.7x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSPPLPHARMA
Promoter Holding72.11%34.86%
FII Holding0%30.18% 0.52 pp
DII Holding0.31% 0.01 pp15.61% 0.08 pp
Public Holding27.58% 0.02 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.